I. Introduction

Benign lymphoid hyperplasia (pseudolymphoma) has been reported in the skin, lungs, orbit, and gastrointestinal tract, but only rarely in soft tissues. Cutaneous pseudolymphoma is a term used to describe a skin lesion that bears a clinical or histological resemblance to lymphoma. Many entities are included under this umbrella based on their lymphoid composition, pattern of infiltration, and associated findings, including cutaneous lymphoid hyperplasia (CLH), pseudolymphomatous folliculitis, Kimura disease, Castleman disease, and pseudo-mycosis fungoides. CLH has had a wide variety of names, including Spiegler-Fendt sarcoid, lymphocytoma cutis, and lymphadenosis benigna cutis. It has a worldwide distribution and affects all races and ethnic groups equally. It occurs both in adults and children, with a slight female predominance. Due to this vast array of characteristics, the lesion is most often not included in the differential diagnosis of soft to firm lumps on the head and neck. A systematic approach to the workup and diagnosis along with treatment of such lesions is discussed in this article.

A 20-year-old Asian Indian female presented to our Oral and Maxillofacial unit with a lump on the left side of her forehead for 1 month. Local examination revealed a 2.5×3.0 cm, well circumscribed swelling over the left para median region that was firm to doughy and non-tender. There was no other significant finding on general examination. Excisional biopsy of the lesion was performed, followed by histopathologic processing. The general etiology, pathogenesis, clinical presentation, differential diagnosis, clinical course, prognosis, treatment, and prevention have been discussed in line with the recent modalities of diagnosis and treatment of CLH. Due to the overlapping clinical and histological characteristics of CLH with many other lesions, it is important to consider this lesion in the differential diagnosis of cutaneous lesions.

II. Case Report

A 20-year-old Asian Indian female presented to our Oral and Maxillofacial unit with a lump on the left side of her forehead. The lump has been present for 1 month, and she had developed a psychological complex due to the unesthetic appearance. The lesion was initially 1×1 cm and had eventually progressed to the presentation size over the month. There was no history of associated fever, previous treatments, unexplained weight loss, or malaise. The patient had no deleterious habits, and the family history was inconclusive for any hereditary or genetic correlation.

General examination did not reveal any significant findings such as similar lesions on the extremities, chest, or abdomen. On further local examination, a 2.5-cm-long and 3-cm-
The histopathological processing showed a highly cellular tissue composed of dense aggregates of lymphocytes with germinal center formation interspersed with abundant mast cells in a scanty stroma. The stroma was composed of loose to dense bundles of collagen fibers forming septae separating the lesional tissue into lobules and forming a capsule. Cut and longitudinal sections of nerve bundles were also seen. Endothelial-lined blood vessels with red blood cells (RBC) and extravasated RBC were noted. These features were suggestive of lymphoid hyperplasia.

The patient underwent regular follow-up for 10 months, and no signs of recurrence, hypoesthesia, or paresthesia were noted.

III. Discussion

1. Etiology and pathogenesis

Most of the commonly diagnosed CLH are thought to be due to idiopathic etiology; however, some may be associated with bites or stings from arthropods, infections such as herpes zoster and Borrelia burgdorferi, recent tattoos, vaccinations, and use of gold jewelry\(^2\). Medications that can be associated with CLH include phenytoin (hydantoin-associated pseudolymphoma syndrome), carbamazepine, phenobarbitols, cyclosporine, calcium channel blockers, and \(H_1\) and \(H_2\) antagonists. Due to this variety of causative agents, the identification of the etiologic factors of this lesion can be considered a very enigmatic dilemma; our case was deemed to be idiopathic. It has been proposed that rather than being the target of the immune response; these agents alter the lymphocyte reactivity in a way to promote a typical CLH response.
2. Clinical findings

Clinical history taking should include the symptomology and duration of the lesion as well as the nature and pace of progression. CLHs are usually slow growing lesions, mostly painless, and have a slow pace of progression with an indefinite rate of growth. The history should also include the so called lymphoma B symptoms such as fever of unknown origin, unexplained weight loss, night sweats, fatigue, and malaise. Our patient did not have any of these symptoms, further lessening the probability of this diagnosis. A general examination should be part of the routine analysis for cutaneous lesions in order to rule out the distribution of skin lesions and peripheral lymph nodes. Extracutaneous involvement should be ruled out by complete blood count, general chemistry panel, and chest radiographs. These lesions are usually solitary but may occur as papules, plaques, or nodules. They usually have a firm to doughy consistency and range from red-brown to violet in color. Use of topical and systemic corticosteroids should be discontinued for at least 4 weeks before biopsy as these agents attenuate the lymphoid infiltrates. The most diagnostic area of biopsy in these lesions is the deepest portion. In our case, i.e., a solitary lesion, it was best to perform an excisional biopsy as the inflammatory changes associated with an incisional biopsy would change the local environment. If uncertainty remains regarding the diagnosis between a pseudo and true lymphoma, further tests may be ordered, such as computed tomography of the chest and abdomen and bone marrow biopsies.

3. Differential diagnosis

The differential diagnoses for an acquired, long standing, painless, firm to doughy lesion occurring on the forehead are numerous, ranging from the benign solitary neurofibroma to malignant lymphomas. The key diagnoses to include are neurofibroma, lipoma, drug eruptions, infectious and inflammatory granulomas, and metastatic carcinoma. It is important to always rule out cutaneous B-cell lymphoma (CBCL) and leukemia cutis, as they are aggressive lesions, and treatment can be completely tangential.

4. Clinical course and prognosis

These lesions can resolve spontaneously, if the etiologic agents are removed, or might persist indefinitely, giving rise to a poor aesthetic outcome. Nodular scabies is a well-known clinical form of persistent CLH that presents as pruritic, persistent nodules for months even after specific treatment. Single standing lesions usually resolve after excisional biopsy. One of the most challenging outcomes is the close relationship with CBCL. Most patients subsequently diagnosed with CBCL receive a previous diagnosis of CLH based on biopsy results. Patients with papulosis, granulomatosis, and lymphadenopathy have a high chance of developing lymphomas. Some authors present this as a "concept of continuum," where the cutaneous pseudolymphomas, such as CLH, represent the benign end of the lymphoproliferative continuum, with the intermediate form being clonal CLH, and the malignant extreme being true lymphomas. This concept is important when considering treatment options based on stage in the continuum, and regular follow up is needed due to the increased risk of clonally related lymphoma and the other lymphoid abnormalities usually associated with this lesion.

5. Treatment

CLH can be treated in a variety of ways based on the etiology. Lymphocytoma cutis, traditionally caused by B. burgdorferi, responds to cyclosporin therapy, as do some of the idiopathic varieties. Glucocorticosteroids (topical, intralesional 5-40 mg/mL 1 mL monthly or systemic 60/40/20 mg 5 days each tapered), hydroxychloroquine 200 mg twice daily, and minocycline 50-100 mg twice daily have been used in the past with varied success. Some studies also support the use of HIV antiviral triple therapy or topical tacrolimus. Radiotherapy has been shown to be effective but is mostly considered a last resort. Recently, the use of pulsed dye lasers and photodynamic therapy has been shown to be effective in esthetic areas. Our case was atypical CLH; in most instances, these lesions cannot be distinguished from true lymphoma, and was hence treated as a localized lymphoma, i.e., excision, after the staging ruled out extra cutaneous disease. Due to the local and distant recurrences after any of the above treatments, this may have been followed by radiotherapy; this was not so in our case due to the patient’s desires.

6. Prevention

Key to the prevention strategy of CLH is to avoid the ingestion of, or contact with, any of the causative agents in patients with a suggestive clinical history, such as anticonvulsants, arthropods, gold jewelry, and hair dyes.

Due to the overlapping clinical and histological character-
istics of CLH with many other lesions, it is important to include and exclude this lesion in the differential diagnoses put forward for suspected cutaneous lesions.

**Conflict of Interest**

No potential conflict of interest relevant to this article was reported.

**ORCID**

Tejraj P. Kale, http://orcid.org/0000-0003-2417-8973
Arjun Gurmeet Singh, http://orcid.org/0000-0002-8119-8439
Pushpak Shah, http://orcid.org/0000-0001-7369-4590

**References**

1. McElroy MK, Kulidjian AA, Sumit R, Weidner N. Benign lymphoid hyperplasia (pseudolymphoma) of soft tissue. Hum Pathol 2011;42:1813-8.
2. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. Fitzpatrick’s dermatology in general medicine. 7th ed. New York: McGraw-Hill; 2008:1407-8.
3. Salama S. Primary cutaneous B-cell lymphoma and lymphoproliferative disorders of skin: current status of pathology and classification. Am J Clin Pathol 2000;114 Suppl:S104-28.
4. Takeda H, Kaneko T, Harada K, Matsuzaki Y, Nakano H, Hanada K. Successful treatment of lymphadenosis benigna cutis with topical photodynamic therapy with delta-aminolevulinic acid. Dermatology 2005;211:264-6.
5. Schartz NE, De La Blanchardiére A, Alaoui S, Morel P, Sigaux F, Vignon-Pennamen MD, et al. Regression of CD8+ pseudolymphoma after HIV antiviral triple therapy. J Am Acad Dermatol 2003;49:139-41.
6. El-Dars LD, Statham BN, Blackford S, Williams N. Lymphocytoma cutis treated with topical tacrolimus. Clin Exp Dermatol 2005;30:305-7.
7. Mikasa K, Watanabe D, Kondo C, Tamada Y, Matsumoto Y. Topical 5-aminolevulinic acid-based photodynamic therapy for the treatment of a patient with cutaneous pseudolymphoma. J Am Acad Dermatol 2005;53:911-2.
8. Arai E, Shimizu M, Tsuchida T, Izaki S, Ogawa F, Hirose T. Lymphomatoid keratosis: an epidermotropic type of cutaneous lymphoid hyperplasia: clinicopathological, immunohistochemical, and molecular biological study of 6 cases. Arch Dermatol 2007;143:53-9.